組合建築市場：現況分析與預測（2023-2030）

Combivir 是拉米夫定和齊多夫定組合的品牌名稱，用於治療人類免疫缺陷病毒/後天免疫缺乏症候群 (HIV)。這些藥物作為抗逆轉錄病毒藥物，透過競爭性抑製或降低逆轉錄□的活性來對抗愛滋病毒。1997年獲得美國食品藥物管理局（FDA）批准。由於無保護性行為、共用受污染的針頭和注射器以及對愛滋病毒傳播方式缺乏認識等因素，導致愛滋病毒診斷和治療日益普遍，Combivir 受到市場關注。例如，《Pan African Medical Journal》2021年發表的一份關於埃塞俄比亞南部Kembata Tembaro Zone公立醫院抗逆轉錄病毒治療期間愛滋病毒感染的報告發現，無保護性行為的發生率為40.9%，其中女性49.4%為男性， 31.5%為男性。幾個因素包括政府關於愛滋病毒傳播方式和可用治療方法的宣傳計劃的激增、口服藥物需求的增加、吸毒成癮率的上升以及政府、公共和私營部門對衛生部門的投資增加。預測期內的市場成長。根據國家藥物濫用統計中心的數據，12歲以上的人中有一半至少使用過一次非法藥物，2020年聯邦藥物管制預算為350億美元。

由於需要遏制愛滋病患者的快速成長，全球製藥公司加大研發投入，Combivir 市場預計將穩定成長 3% 左右。例如，據美國癌症研究所估計，2021 年全球將有 3 萬癌症患者。其他幾個因素，例如仿製藥的引入、其成本效益以及政府措施也在穩步推動這一 Combivir 市場的發展。例如，美國衛生與公眾服務部 (HHS) 於 2019 年啟動了結束愛滋病毒流行 (EHE) 計劃，其雄心勃勃的目標是到 2030 年將美國新發愛滋病毒感染人數減少 90%。HHS 也為司法管轄區提供多種資助機會，包括對性傳染病診所的同時投資。

按類型劃分，市場分為品牌產品和通用產品。2022年，在全球組合建築市場中，品牌細分市場將佔最大份額。由於該品牌的良好聲譽，該細分市場在市場上佔據主導地位。因此，許多消費者紛紛湧向品牌藥品。因此，由於上述原因，品牌細分市場將在 2022 年佔據主要市場份額。

根據應用，市場分為非職業暴露和職業暴露。由於工作量、工作時間長和時間壓力導致醫療中心的傷亡人數不斷增加，職業暴露細分市場預計在預測期內將佔據相當大的市場份額。例如，商業情報公司Definitive Healthcare在2022年發布報告稱，2021年，估計有33.3萬名醫護人員報告職業倦怠程度高、工作時間長、患者工作量繁重。他表示，自己離職是因為這個的。除此之外，越來越多的毒癮病例增加了醫院的病患負擔，也推動了這一領域的成長。因此，在應用中，職業暴露類別預計在預測期內將出現較高的複合年增長率。

為了更了解Combivir的市場介紹，市場為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度） ） 。，亞太地區其他地區），以及世界其他地區中東和非洲。由於愛滋病毒感染人數不斷增加、毒癮增加以及開發有效治療方法的投資不斷增加，到 2022 年，北美將佔據全球 Combivir 市場的大部分。政府機構已啟動愛滋病宣傳計劃，為病患提供有效的照護。例如，美國《2022-2025 年國家愛滋病毒/愛滋病戰略》旨在對所有公民進行有關愛滋病毒/愛滋病的教育，包括愛滋病毒傳播、預防和構成最大感染風險的行為。因此，2022年北美將佔據很大的市場份額。

目錄

第一章 市場介紹

• 市場定義
• 主要目標
• 利益相關者
• 限制

第二章 研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對組合建築市場的影響

第六章 組合建築市場收入，2020-2030

第 7 章按類型劃分的市場洞察

• 牌
• 通用的

第 8 章按應用劃分的市場洞察

• 非職業暴露
• 職業接觸

第 9 章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 北美其他地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 亞太其他地區
• 世界其他地區 中東/非洲

第10章組合建築市場動態

• 市場驅動力
• 市場挑戰
• 影響分析

第十一章 Combi 建構市場機會

第十二章組合建築市場趨勢

第十三章需求面與供給面分析

• 需求面分析
• 供給側分析

第十四章價值鏈分析

第15章 競爭場景

• 競爭格局
  • 波特五力分析

第十六章公司簡介

• Mylan Inc.
• Macleods Pharmaceuticals Ltd.
• Lupin
• Aurobindo Pharma
• Pfizer Inc.
• Cipla Inc.
• ViiV Healthcare group of companies
• Hetero
• Strides Pharma Science Limited
• GSK plc.

第十七章 免責聲明

Combivir is the brand name for a combination of drugs lamivudine and zidovudine used to treat Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV). These drugs act as antiretroviral agents and fight against HIV by competitively inhibiting and reducing the activity of reverse transcriptase. It was initially approved in 1997 by the U.S. Food and Drug Administration. Combivir is gaining prominence in the market owing to the increasing prevalence of HIV diagnosis and treatment due to unprotected coitus, sharing of contaminated needles or syringes, absence of awareness about the mode of transmission of HIV. For instance, in 2021, according to the Pan African Medical Journal's report of HIV on antiretroviral therapy in public hospitals of Kembata Tembaro Zone, Southern Ethiopia, the prevalence of unprotected sex was (40.9%) among which there were 49.4% of females and 31.5% of males. Several factors, including a surge in the increasing government awareness programs regarding the mode of transmission of HIV and available treatment options for HIV, rising demand for oral drugs, rising drug addiction rate, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the National Center for Drug Abuse Statistics, half of people 12 and older have used illicit drugs at least once and the federal budget for drug control in 2020 was USD 35 billion.

The Combivir Market is expected to grow at a steady rate of around 3% owing to the increased investment in research & development globally by pharmaceutical companies due to the surge in AIDS cases which needs to be controlled. For instance, according to U.S. HIV.gov, in 2021, there were 32,100 estimated new HIV infections in the U.S. Many new therapies are being introduced for treating this deadly retrovirus. Several other factors, such as the introduction of generic drugs and their cost-effectiveness, and government initiatives are also driving this market of combivir at a steady rate. For instance, the U.S.-based Department of Health and Human Services (HHS) initiated a program the ' Ending the HIV Epidemic (EHE)' in 2019 with an ambitious goal of reducing all new HIV infections in the U.S. by 90% by 2030. HHS has also provided multiple funding opportunities to jurisdictions, including simultaneous investments in sexually transmitted diseases specialty clinics.

Based on type, the market is bifurcated into branded and generic. The branded segment held the maximum share in the global market of combivir in 2022. This segment dominated the market because of their good brand reputation . This draws a maximum number of consumers towards branded drugs. Hence, due to the above reasons, the branded segment held a significant share of the market in 2022.

Based on application, the market is bifurcated into nonoccupational exposure and occupational exposure. The occupational exposure segment is expected to hold a significant share of the market in the forecast period owing to the increased number of casualties in healthcare centers owing to workload, long working hours, and time pressure. For instance, a commercial intelligence company Definitive Healthcare published a report in 2022 saying an estimated 333,000 healthcare providers left their jobs in 2021, due to burnout, long hours, and heavy patient loads. Apart from this, the rising number of cases of drug addiction is boosting the patient load in hospitals and is also impelling the growth of this segment. Hence, amongst applications, the occupational exposure category is expected to witness higher CAGR during the forecast period.

For a better understanding of the market adoption of combivir, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global combivir market in the year 2022 due to the increasing HIV cases, increasing drug addiction, and rising number of investments in developing effective therapeutics. Government organizations are initiating AIDS awareness programs to provide efficient care to patients. For instance, the U.S.-based National HIV/AIDS Strategy for 2022-2025 aims to educate all its citizens regarding HIV/AIDS including HIV transmission, prevention, and behaviors that place individuals at greatest risk for infection. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include: Mylan Inc.; Macleods Pharmaceuticals Ltd.; Lupin; Aurobindo Pharma; Pfizer Inc.; Cipla Inc.; ViiV Healthcare group of companies; Hetero; Strides Pharma Science Limited; GSK plc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Combivir Market
• 2.2. Research Methodology of the Combivir Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE COMBIVIR MARKET

6 COMBIVIR MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Branded
• 7.2. Generic

8 MARKET INSIGHTS BY APPLICATIONS

• 8.1. Nonoccupational Exposure
• 8.2. Occupational Exposure

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 COMBIVIR MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 COMBIVIR MARKET OPPORTUNITIES

12 COMBIVIR MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Mylan Inc.
• 16.2. Macleods Pharmaceuticals Ltd.
• 16.3. Lupin
• 16.4. Aurobindo Pharma
• 16.5. Pfizer Inc.
• 16.6. Cipla Inc.
• 16.7. ViiV Healthcare group of companies
• 16.8. Hetero
• 16.9. Strides Pharma Science Limited
• 16.10. GSK plc.

17 DISCLAIMER